收藏切换
Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients
收藏切换
Xiaozun YANG1, Qiang LI1, 2, *
World Clinical Drug | 2024, 45(5) : 514 - 520
Less
收藏切换
World Clinical Drug | 2024, 45(5): 514-520
• Article •
Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients
Full
Xiaozun YANG1, Qiang LI1, 2, *
Affiliations
  • 1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China
  • 2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China
Published: 2024-05-10 doi: 10.13683/j.wph.2024.05.011
Outline
收藏切换
Objective

To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer (NSCLC) patients.

Methods

This prospective, single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery. Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery. After discharge, patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter. The primary outcome was pathological remission rate. Secondary outcome measures were clinical response rate, disease-free survival (DFS), and overall survival (OS).

Results

The mean age of all enrolled patients was (59.84±7.14) years, including 18 males (72.00%) and 7 females (28.00%). The primary outcome indicated that 56% patients achieved significant pathological response, among which 24% achieved complete pathological response. The secondary outcome showed that 0, 60%, 36% and 4% patients achieved clinical complete response, partial response, disease stability and disease progression, and the overall objective response rate was 60%. The 1-year DFS was 79%, and the 1-year OS was 90%. There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS. Besides, The most common adverse events were alopecia (48%), fatigue (40%), nausea and vomiting (36%). Most of the adverse events were at grade 1 to 2, only a few were at grade 3 to 4.

Conclusion

Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.

durvalumab  /  cisplatin and docetaxel  /  neoadjuvant therapy  /  locally advanced non-small cell lung cancer  /  efficacy  /  safety
杨晓樽, 李强. 度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效评估. 世界临床药物, 2024 , 45 (5) : 514 -520 . DOI: 10.13683/j.wph.2024.05.011
Xiaozun YANG, Qiang LI. Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients[J]. World Clinical Drug, 2024 , 45 (5) : 514 -520 . DOI: 10.13683/j.wph.2024.05.011
Year 2024 volume 45 Issue 5
19
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.05.011
  • Receive Date:2023-10-15
  • Online Date:2026-11-17
  • Published:2024-05-10
Article Data
Affiliations
History
  • Received:2023-10-15
Affiliations
    1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China
    2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.05.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT